We are live on
!
Find out more
VCG
Vantage Consulting Group Portfolio holdings
AUM
$19.7M
1-Year Est. Return
280.87%
This Fund
S&P 500
This Quarter
Est. Return
+17.65%
1 Year Est. Return
+280.87%
3 Year Est. Return
+261.08%
5 Year Est. Return
+180.34%
10 Year Est. Return
–
AUM
$1.23B
AUM Growth
–
Cap. Flow
+$1.06B
Cap. Flow
% of AUM
86.51%
Top 10 Holdings %
Top 10 Hldgs %
94.5%
Holding
1,884
New
1,883
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Royalty Pharma
RPRX
|
+$911M |
| 2 |
ADC Therapeutics
ADCT
|
+$55.1M |
| 3 |
KYNB
Kyntra Bio
KYNB
|
+$25.5M |
| 4 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$5.96M |
| 5 |
Kroger
KR
|
+$366K |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.04% |
| 2 | Technology | 0.89% |
| 3 | Consumer Discretionary | 0.79% |
| 4 | Industrials | 0.61% |
| 5 | Consumer Staples | 0.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
351
Idexx Laboratories
IDXX
$46.4B
| $65K | 0.01% |
+130
| New | +$58.2K |
|
352
Leggett & Platt
LEG
$1.43B
| $65K | 0.01% |
+1,467
| New | +$62.9K |
|
353
Pfizer
PFE
$145B
| $65K | 0.01% |
+1,771
| New | +$65K |
|
354
Rambus
RMBS
$10.9B
| $65K | 0.01% |
+3,748
| New | +$58.8K |
|
355
Universal Corp
UVV
$1.32B
| $65K | 0.01% |
+1,334
| New | +$60.1K |
|
|
IVC
356
DELISTED
Invacare Corporation
IVC
| $65K | 0.01% |
+7,300
| New | +$60.7K |
|
|
CATM
357
DELISTED
Cardtronics plc Class A Ordinary Shares (UK)
CATM
| $65K | 0.01% |
+1,829
| New | +$45.7K |
|
358
ANI Pharmaceuticals
ANIP
$1.8B
| $64K | 0.01% |
+2,208
| New | +$63.2K |
|
359
Boston Scientific
BSX
$71.1B
| $64K | 0.01% |
+1,778
| New | +$64.1K |
|
360
United Airlines
UAL
$43B
| $64K | 0.01% |
+1,488
| New | +$60.2K |
|
361
Zimmer Biomet
ZBH
$18.5B
| $64K | 0.01% |
+430
| New | +$60.7K |
|
362
Bank of America
BAC
$440B
| $63K | 0.01% |
+2,067
| New | +$55.4K |
|
363
DexCom
DXCM
$32.8B
| $63K | 0.01% |
+680
| New | +$60.7K |
|
364
JPMorgan Chase
JPM
$950B
| $63K | 0.01% |
+498
| New | +$55.7K |
|
365
Citigroup
C
$230B
| $62K | 0.01% |
+1,005
| New | +$51.1K |
|
366
ResMed
RMD
$32.4B
| $62K | 0.01% |
+292
| New | +$58.2K |
|
367
Skywest
SKYW
$4.56B
| $62K | 0.01% |
+1,536
| New | +$56.1K |
|
368
Stryker
SYK
$129B
| $62K | 0.01% |
+255
| New | +$57.8K |
|
369
Wells Fargo
WFC
$267B
| $62K | 0.01% |
+2,041
| New | +$52.8K |
|
|
VGR
370
DELISTED
Vector Group Ltd.
VGR
| $62K | 0.01% |
+7,470
| New | +$58.6K |
|
371
American Coastal Insurance
ACIC
$535M
| $61K | 0.01% |
+10,727
| New | +$54.2K |
|
372
Align Technology
ALGN
$12.4B
| $61K | 0.01% |
+115
| New | +$51.7K |
|
373
Pathward Financial
CASH
$1.89B
| $61K | 0.01% |
+1,675
| New | +$51K |
|
374
Fortune Brands Innovations
FBIN
$6.29B
| $61K | 0.01% |
+827
| New | +$60.3K |
|
375
Mohawk Industries
MHK
$9.25B
| $61K | 0.01% |
+436
| New | +$52.5K |
|
Similar funds
MVG
NCM
FFGIM
PIM
HFG
SWM
ICM
SM
Vantage Consulting Group's Q4 2020 Portfolio in Review
Q4 2020 is the first quarter with a 13F filing on record for Vantage Consulting Group, which disclosed 1,884 positions worth $1.23B. Its ten largest holdings account for 94% of the portfolio.
Its largest position is Royalty Pharma: 21,477,282 shares worth $1.07B.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, followed by Technology and Consumer Discretionary.
- Vantage Consulting Group's largest Q4 2020 buy was Royalty Pharma: 21,477,282 shares worth $1.07B.
- Vantage Consulting Group's ten largest holdings make up 94% of its $1.23B portfolio in Q4 2020.
- Vantage Consulting Group disclosed 1,884 positions in Q4 2020, its first 13F filing on record.
Based on Vantage Consulting Group's 13F filing for Q4 2020, filed 12 Feb 2021.